Evidence map›Paper›PMID 26631690›Full record

ArticleScientific reports2015

TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma.

Martina Damo, David S Wilson, Eleonora Simeoni, Jeffrey A Hubbell

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 140 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Exosome-based approaches in the management of Alzheimer's disease.Neuroscience and biobehavioral reviews · 2023
    Review
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Martina DamoInstitute of Bioengineering, School of Life Sciences and School of Engineering, Ecole Polytechnique Fédérale Lausanne, CH-1015 Lausanne, Switzerland.
David S WilsonInstitute of Bioengineering, School of Life Sciences and School of Engineering, Ecole Polytechnique Fédérale Lausanne, CH-1015 Lausanne, Switzerland.
Eleonora SimeoniInstitute of Bioengineering, School of Life Sciences and School of Engineering, Ecole Polytechnique Fédérale Lausanne, CH-1015 Lausanne, Switzerland.
Jeffrey A HubbellInstitute of Bioengineering, School of Life Sciences and School of Engineering, Ecole Polytechnique Fédérale Lausanne, CH-1015 Lausanne, Switzerland.
École Polytechnique Fédérale de Lausanne · CHUniversity of Chicago · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dendritic cell (DC)-derived exosomes (Dexo) contain the machinery necessary to activate potent antigen-specific immune responses. As promising cell-free immunogens, Dexo have been tested in previous clinical trials for cancer vaccine immunotherapy, yet resulted in limited therapeutic benefit. Here, we explore a novel Dexo vaccine formulation composed of Dexo purified from DCs loaded with antigens and matured with either the TLR-3 ligand poly(I:C), the TLR-4 ligand LPS or the TLR-9 ligand CpG-B. When poly(I:C) was used to produce exosomes together with ovalbumin (OVA), the resulting Dexo vaccine strongly stimulated OVA-specific CD8(+) and CD4(+) T cells to proliferate and acquire effector functions. When a B16F10 melanoma cell lysate was used to load DCs with tumor antigens during exosome production together with poly(I:C), we obtained a Dexo vaccine capable of inducing robust activation of melanoma-specific CD8(+) T cells and the recruitment of cytotoxic CD8(+) T cells, NK and NK-T cells to the tumor site, resulting in significantly reduced tumor growth and enhanced survival as compared to a Dexo vaccine formulation similar to the one previously tested on human patients. Our results indicate that poly(I:C) is a particularly favorable TLR agonist for DC maturation during antigen loading and exosome production for cancer immunotherapy.

Indexed as

AnimalsCancer VaccinesCD8-Positive T-LymphocytesDendritic CellsExosomesFemaleImmunotherapyKiller Cells, NaturalLipopolysaccharidesMelanoma, ExperimentalMice, Inbred C57BLMice, TransgenicOvalbuminToll-Like Receptor 3Cancer VaccinesLipopolysaccharidesOvalbuminTLR3 protein, mouseToll-Like Receptor 3

Identifiers

PMID26631690
PMCPMC4668567
OpenAlexW2320752006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.